Glycogen Synthase Kinase-3 (GSK3), Lithium and Fragile X

Glycogen Synthase Kinase-3 (GSK3), Lithium and Fragile X

With $208,000 in funds from FRAXA Research Foundation, Dr. Richard Jope and his team at the University of Miami tested whether newly developed, highly specific inhibitors of GSK3 can reduce behavioral abnormalities in Fragile X mice.

Read more